Welcome to Artimmune - Your trusted partner in drug discovery for inflammation and infection. With a focus on scientific expertise, collaboration, and reliability, we are dedicated to advancing research in immunology and inflammation. As the world faces the challenges of COVID-19, Artimmune is committed to providing optimized research solutions. Our murine model of cytokine storm aids in the investigation of new drug candidates to combat COVID-19. Explore our preclinical CRO services and benefit from our extensive experience in lung diseases and immunology. Contact us to drive your research projects forward.
In vitro studies are designed by Artimmune scientists to assess cellular toxicity and proof of concept of tested compounds, an essential step prior to animal and human studies. Our expertise and facilities (BSL1 and BSL2 laboratories) allow us to perform a study from conception and design to bench and analysis.
Bone-marrow derived | Macrophages | |
---|---|---|
Dendritic cells | ||
Cell isolation | T cells | |
Fibroblasts | ||
Hepatocytes | ||
IELs | ||
Cell lines | hAEC | Human Airway Epithelial cells of bronchiolar origin |
NHBE | Human primary bronchial Tracheal Epithelial cells | |
hPBMC | Human Peripheral Blood Mononuclear cells |
Mouse | Raw 264.7 | Macrophages |
---|---|---|
Human | A549 | Epithelial cells |
Beas2B | Bronchial epithelial cells | |
SW-1116 | Colon adenocarcinoma | |
PL-45 | Pancreatic carcinoma | |
RKO | Colon adenocarcinoma | |
HPAF-II | Pancreas adenocarcinoma | |
BxPC-3 | Pancreatic carcinoma | |
PC-3 | Prostate adenocarcinoma | |
DU-145 | Prostate carcinoma | |
UM-UC-3 | Urinary bladder carcinoma | |
NCI-H292 | Lung carcinoma | |
Dog | MDCK(NBL-2) | Kidney |
DH82 | Malignant histiocytosis |